CJC-1295 (no DAC)
CJC-1295 without DAC is a GHRH analogue used in growth-hormone axis research. The DAC-free form has the shorter half-life and is typically researched in combination.
Also known as: Modified GRF (1-29)
Research context
- GHRH analogue; the 'no DAC' variant is the short-acting form.
- Usually paired with a secretagogue such as ipamorelin.
- Supplied as a single 10mg presentation.
Full breakdown below: what CJC-1295 is • how it sits in the growth-hormone category • supply and handling • common questions
CJC-1295 (no DAC)
from £32.30 per vial
| Strength | Price | |
|---|---|---|
| 10mg | £32.30bank £29.07 | Buy vial |
Bank transfer prices shown under each card price (10% off). Checkout runs on Stripe; bank orders confirm on clearance.
What CJC-1295 is
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). The name comes from its developer, the drug company that modified the natural GHRH sequence so the molecule is more stable in circulation. The “no DAC” form you can order here is the version without a drug-affinity complex (DAC): without the DAC the peptide has a short half-life and must be dosed more frequently, which is why it is the form most often used in research protocols that want tight control over when the GH pulse happens and how long it lasts.
It is a GHRH-receptor agonist, which puts it in the same receptor family as tesamorelin (the clinically approved GHRH analogue) but with a very different documentation profile: CJC-1295 is widely used in research but has never completed a pivotal clinical programme, so the published evidence base is thinner and more preclinical/early-phase than tesamorelin’s.
Where it sits in the growth-hormone category
The growth-hormone shelf splits into two mechanisms: GHRH analogues that work on the GHRH receptor (tesamorelin, CJC-1295), and ghrelin-receptor secretagogues that work on the ghrelin receptor (ipamorelin, GHRP-2, GHRP-6). The two mechanisms are complementary, which is why the standard research pairing on this shelf is CJC-1295 (no DAC) + ipamorelin — see the CJC-1295 + Ipamorelin page for how that combination is presented.
| Compound | Receptor / class | Half-life character | Clinical documentation |
|---|---|---|---|
| Tesamorelin | GHRH analogue | Long-acting (single daily research dose in published studies) | Completed pivotal programme; approved product in the US |
| CJC-1295 (no DAC) | GHRH analogue | Short-acting (minutes-scale pulses) | Preclinical + early-phase; no completed pivotal programme |
| Ipamorelin | Ghrelin-receptor agonist | Moderate | Clinical studies; not approved as a product |
| GHRP-2 / GHRP-6 | Ghrelin-receptor agonists | Short | Preclinical + early-phase |
The practical takeaway: if the research question is “how does the GHRH-receptor pathway behave with tight pulse control”, CJC-1295 (no DAC) is the right tool because its short half-life is the feature, not a limitation. If you want the better-characterised reference compound on that same receptor, that is tesamorelin.
How it is supplied and handled
CJC-1295 (no DAC) ships as a lyophilised (freeze-dried) powder in a sealed vial — the standard stable form for research peptides. It is available here as a single 10mg presentation. Once reconstituted with bacteriostatic water it should be kept refrigerated and handled cold-chain; the general reconstitution guide covers the volumes, the arithmetic and the storage handling that apply to this class of compound.
Every batch is supplied with a certificate of analysis. Our lab and COA policy explains what is tested and what the documentation covers — if you need a batch-specific COA before ordering, ask via the contact page and we will send it.
Ordering, payment and delivery
Pricing is per single vial — no minimum order. Card checkout runs on Stripe; bank transfer is available at 10% off and confirms on clearance. UK dispatch is cold-chain, and delivery sets out the timelines and what to expect on arrival.
Common questions
What is the difference between CJC-1295 and CJC-1295 with DAC?
The DAC (drug-affinity complex) binds to the peptide and extends its half-life dramatically, so the with-DAC form is long-acting and the no-DAC form is short-acting. The no-DAC form is the one most often researched where frequent, controlled dosing is desired; the with-DAC form is less commonly handled. We stock the no-DAC form.
Is CJC-1295 a GHRH agonist or a ghrelin agonist?
It is a GHRH-receptor agonist, like tesamorelin. It is not a ghrelin-receptor compound — that is the ipamorelin / GHRP-2 / GHRP-6 side of the shelf.
Why is it usually paired with ipamorelin?
Because the two mechanisms are complementary: CJC-1295 stimulates the GHRH receptor and ipamorelin stimulates the ghrelin receptor, so in research protocols they are combined to hit both secretagogue pathways. See the CJC-1295 + Ipamorelin page for the combination presentation.
How is CJC-1295 documented compared with tesamorelin?
Less. Tesamorelin has a completed pivotal clinical programme and an approved US product; CJC-1295’s evidence base is preclinical and early-phase. If the research question needs the best-characterised GHRH-receptor reference compound, tesamorelin is the cleaner choice.
What strength do you stock and how do I pay?
Single 10mg vial at £32.30 by card, £29.07 by bank transfer. No minimum order; card checkout runs on Stripe, bank orders confirm on clearance.
Is CJC-1295 a medicine?
As sold here it is a research chemical. It is not a licensed medicine in the UK, it is not for human or veterinary use, and nothing on this page is medical advice or a dosing recommendation.